Where are you?
To give you the most accurate information about our products and what we can do for you, we need to direct you to the right site.
USA
International
Media and Investors Resources
Press Release, 5 October 2020
Kuros announces all agenda items were approved at its Extraordinary General Meeting today and launches a discounted rights offering expected to raise up to CHF 15.2 million of gross proceeds
Press Release, 5 October 2020
Kuros Biosciences reports MagnetOs products approved in Australia
Press Release, 1 October 2020
Kuros Biosciences Hosts an Expert Perspectives Webinar on Pioneering Solutions for Targeted and Controlled Bone Healing
Press Release, 21 September 2020
Kuros reaches milestone of 2,000 patients treated with MagnetOs bone graft
Press Release, 11 September 2020
Kuros Convenes Extraordinary General Meeting
Press Release, 9 September 2020
Kuros Biosciences's licensee Checkmate Pharmaceuticals completes its IPO on NASDAQ